Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
Archives de la catégorie : 2025
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates First Close of Series B financing raises €10 million Meiji Seika Pharma Co., Ltd joins as new international investor Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates Lyon, France – March 4, 2025 – Osivax, a …